Skip to main content
ERAS
NASDAQ Life Sciences

Erasca's ERAS-0015 Posts 44% ORR in Pancreatic Cancer; Phase 3 Moved Up to 1H 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$13.75
Mkt Cap
$4.991B
52W Low
$2.75
52W High
$24.28
52W Position info
400% above low
Off High info
43% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ERAS has more than doubled off its 52-week low of $2.75.

Summary

Erasca reported a 44% confirmed ORR for ERAS-0015 in 2L+ KRAS G12X pancreatic cancer and 69% in the G12D/G12V subtypes, with clean safety at the 32 mg dose. The company is accelerating the first-line pancreatic Phase 3 start to the first half of 2027.


Key Events · Product Development and Regulatory · ERAS

  • 44% ORR in Pancreatic Cancer

    At 32 mg once daily, ERAS-0015 produced a 44% confirmed objective response rate across 25 patients with KRAS G12X pancreatic ductal adenocarcinoma in the 2L+ setting; 84% were treated in the third line or later.

  • 69% ORR in G12D/G12V Subtypes

    Confirmed ORR reached 69% (N=13) in KRAS G12D or G12V pancreatic cancer, subtypes representing nearly 70% of PDAC patients, split into 63% (N=8) for G12D and 80% (N=5) for G12V.

  • Clean Safety at Active Dose

    At 32 mg once daily (N=54), there were no dose-limiting toxicities and no dose discontinuations, with 13.0% dose interruptions, 16.7% dose reductions and 100% median relative dose intensity.

  • Phase 3 Accelerated to 1H 2027

    The first-line pancreatic cancer Phase 3 trial start was pulled forward to the first half of 2027, and a potentially registration-enabling 2L+ RAS-mutant NSCLC trial is expected in the same window.


Analysis · ERAS · Life Sciences

Erasca now holds a clinical dataset that supports a best-in-class claim for its pan-RAS molecular glue. In 2L+ KRAS G12X pancreatic cancer, ERAS-0015 at 32 mg once daily delivered a 44% confirmed objective response rate across 25 patients, rising to 69% in the G12D/G12V subtypes that account for nearly 70% of pancreatic cancer. Durability held up: all 11 responders remained on treatment. Safety at the active dose looks manageable, with no dose-limiting toxicities, no discontinuations at 32 mg, and 100% median relative dose intensity. The company is pulling its first-line pancreatic Phase 3 start forward to the first half of 2027 and now plans a potentially registration-enabling 2L+ NSCLC trial in the same window. With $947.8 million in cash as of September 30, this is the kind of data that shifts the pipeline from speculative to near-registrational. Two caveats remain: these are interim results from small cohorts, and the previously disclosed Revolution Medicines patent and trade-secret allegations against ERAS-0015 are still unresolved.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ERAS was trading at $13.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5B. The 52-week trading range was $2.75 to $24.28. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ERAS - Latest Insights

ERAS
Nov 20, 2026, 10:40 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $14.01
Real-time Price: $13.61 info
Change: -$0.400 (-3%) info
Market Cap: $4.789B info
ERAS
Nov 20, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $13.99
Real-time Price: $13.61 info
Change: -$0.380 (-3%) info
Market Cap: $4.789B info
ERAS
Nov 17, 2026, 6:40 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $13.99
Real-time Price: $13.61 info
Change: -$0.380 (-3%) info
Market Cap: $4.789B info
ERAS
Nov 12, 2026, 4:03 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $13.61 info
Change: -$2.17 (-14%) info
Market Cap: $4.789B info
ERAS
Nov 12, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $13.61 info
Change: -$2.17 (-14%) info
Market Cap: $4.789B info